Eckardt Lars
Klinik für Kardiologie II - Rhythmologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland.
Herzschrittmacherther Elektrophysiol. 2020 Mar;31(1):39-47. doi: 10.1007/s00399-020-00667-x. Epub 2020 Jan 31.
Brugada syndrome is ion channelopathy defined by coved type ST-elevation in at least one right precordial ECG lead. Patients may suffer from ventricular tachycardia/fibrillation, which may cause syncope or sudden cardiac death. The majority of patients are likely to remain asymptomatic throughout life. A correct ECG diagnosis remains challenging. The implantable cardioverter/defibrillator (ICD) is the only established therapy to protect against sudden cardiac death. Thus, individual risk stratification is of major clinical relevance in primary prevention. The present article gives an update on current risk stratification and novel therapeutic options apart from ICD therapy.
Brugada综合征是一种离子通道病,其定义为至少一个右胸前心电图导联出现穹窿型ST段抬高。患者可能会发生室性心动过速/心室颤动,这可能导致晕厥或心源性猝死。大多数患者可能终生无症状。正确的心电图诊断仍然具有挑战性。植入式心脏复律除颤器(ICD)是预防心源性猝死的唯一既定疗法。因此,个体风险分层在一级预防中具有重要的临床意义。本文介绍了当前风险分层以及除ICD治疗之外的新型治疗选择的最新情况。